NCT06688838View on ClinicalTrials.gov

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

Enrolling by invitationOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Blau Syndrome
Interventions
DRUG

Tofacitinib

If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.

Trial Locations (1)

430030

Yikai YU, Wuhan

All Listed Sponsors
collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Affiliated Hospital of Yunnan University

OTHER

lead

Tongji Hospital

OTHER